Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

RUTI Vaccination Enhances Inhibition of Mycobacterial Growth ex vivo and Induces a Shift of Monocyte Phenotype in Mice.

Prabowo SA, Painter H, Zelmer A, Smith SG, Seifert K, Amat M, Cardona PJ, Fletcher HA.

Front Immunol. 2019 Apr 30;10:894. doi: 10.3389/fimmu.2019.00894. eCollection 2019.

2.

In vitro Mycobacterial Growth Inhibition in South Korean Adults With Latent TB Infection.

Lee H, Kim J, Kang YA, Kim DR, Sim B, Zelmer A, Fletcher HA, Dockrell HM, Smith SG, Cho SN.

Front Immunol. 2019 Apr 26;10:896. doi: 10.3389/fimmu.2019.00896. eCollection 2019.

3.

Author Correction: The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays.

Tanner R, O'Shea MK, White AD, Müller J, Harrington-Kandt R, Matsumiya M, Dennis MJ, Parizotto EA, Harris S, Stylianou E, Naranbhai V, Bettencourt P, Drakesmith H, Sharpe S, Fletcher HA, McShane H.

Sci Rep. 2019 Apr 3;9(1):5596. doi: 10.1038/s41598-019-41387-8.

4.

Historical BCG vaccination combined with drug treatment enhances inhibition of mycobacterial growth ex vivo in human peripheral blood cells.

Prabowo SA, Zelmer A, Stockdale L, Ojha U, Smith SG, Seifert K, Fletcher HA.

Sci Rep. 2019 Mar 19;9(1):4842. doi: 10.1038/s41598-019-41008-4.

5.

Regulation of mycobacterial infection by macrophage Gch1 and tetrahydrobiopterin.

McNeill E, Stylianou E, Crabtree MJ, Harrington-Kandt R, Kolb AL, Diotallevi M, Hale AB, Bettencourt P, Tanner R, O'Shea MK, Matsumiya M, Lockstone H, Müller J, Fletcher HA, Greaves DR, McShane H, Channon KM.

Nat Commun. 2018 Dec 20;9(1):5409. doi: 10.1038/s41467-018-07714-9.

6.

Systems approaches to correlates of protection and progression to TB disease.

Fletcher HA.

Semin Immunol. 2018 Oct;39:81-87. doi: 10.1016/j.smim.2018.10.001. Epub 2018 Oct 10. Review.

PMID:
30316693
7.

Glibenclamide Reduces Primary Human Monocyte Functions Against Tuberculosis Infection by Enhancing M2 Polarization.

Kewcharoenwong C, Prabowo SA, Bancroft GJ, Fletcher HA, Lertmemongkolchai G.

Front Immunol. 2018 Sep 19;9:2109. doi: 10.3389/fimmu.2018.02109. eCollection 2018.

8.

Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making.

Rhodes SJ, Guedj J, Fletcher HA, Lindenstrøm T, Scriba TJ, Evans TG, Knight GM, White RG.

NPJ Vaccines. 2018 Sep 17;3:36. doi: 10.1038/s41541-018-0075-3. eCollection 2018.

9.

High monocyte to lymphocyte ratio is associated with impaired protection after subcutaneous administration of BCG in a mouse model of tuberculosis.

Zelmer A, Stockdale L, Prabowo SA, Cia F, Spink N, Gibb M, Eddaoudi A, Fletcher HA.

Version 2. F1000Res. 2018 Mar 8 [revised 2018 Jan 1];7:296. doi: 10.12688/f1000research.14239.2. eCollection 2018.

10.

VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy.

Fletcher HA, Chatterjee M, Cooper A, Hussell T, Kaye PM, Prior J, Reljic R, Vermaak S, Vordermeier M, Williams A, McShane H.

F1000Res. 2018 Apr 23;7:485. doi: 10.12688/f1000research.14386.1. eCollection 2018.

11.

Social determinants and BCG efficacy: a call for a socio-biological approach to TB prevention.

Dowd JB, Fletcher HA, Boccia D.

F1000Res. 2018 Feb 23;7:224. doi: 10.12688/f1000research.14085.1. eCollection 2018.

12.

Progress and challenges in TB vaccine development.

Voss G, Casimiro D, Neyrolles O, Williams A, Kaufmann SHE, McShane H, Hatherill M, Fletcher HA.

F1000Res. 2018 Feb 16;7:199. doi: 10.12688/f1000research.13588.1. eCollection 2018. Review.

13.

World TB Day 2018: The Challenge of Drug Resistant Tuberculosis.

Gupta-Wright A, Tomlinson GS, Rangaka MX, Fletcher HA.

F1000Res. 2018 Feb 22;7:217. doi: 10.12688/f1000research.14088.1. eCollection 2018.

14.

The Cross-Species Mycobacterial Growth Inhibition Assay (MGIA) Project, 2010-2014.

Brennan MJ, Tanner R, Morris S, Scriba TJ, Achkar JM, Zelmer A, Hokey DA, Izzo A, Sharpe S, Williams A, Penn-Nicholson A, Erasmus M, Stylianou E, Hoft DF, McShane H, Fletcher HA.

Clin Vaccine Immunol. 2017 Sep 5;24(9). pii: e00142-17. doi: 10.1128/CVI.00142-17. Print 2017 Sep. Review.

15.

The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays.

Tanner R, O'Shea MK, White AD, Müller J, Harrington-Kandt R, Matsumiya M, Dennis MJ, Parizotto EA, Harris S, Stylianou E, Naranbhai V, Bettencourt P, Drakesmith H, Sharpe S, Fletcher HA, McShane H.

Sci Rep. 2017 Mar 3;7:43478. doi: 10.1038/srep43478. Erratum in: Sci Rep. 2019 Apr 3;9(1):5596.

16.

Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study.

Andrews JR, Nemes E, Tameris M, Landry BS, Mahomed H, McClain JB, Fletcher HA, Hanekom WA, Wood R, McShane H, Scriba TJ, Hatherill M.

Lancet Respir Med. 2017 Apr;5(4):282-290. doi: 10.1016/S2213-2600(17)30060-7. Epub 2017 Feb 16.

17.

Human Immunology of Tuberculosis.

Scriba TJ, Coussens AK, Fletcher HA.

Microbiol Spectr. 2017 Jan;5(1). doi: 10.1128/microbiolspec.TBTB2-0016-2016. Review.

18.

Human Immunology of Tuberculosis.

Scriba TJ, Coussens AK, Fletcher HA.

Microbiol Spectr. 2016 Oct;4(5). doi: 10.1128/microbiolspec.TBTB2-0016-2016. Review.

PMID:
27740453
19.

Human Immunology of Tuberculosis.

Scriba TJ, Coussens AK, Fletcher HA.

Microbiol Spectr. 2016 Aug;4(4). doi: 10.1128/microbiolspec.TBTB2-0016-2016. Review.

PMID:
27726784
20.

Polyfunctional CD4 T-cells correlate with in vitro mycobacterial growth inhibition following Mycobacterium bovis BCG-vaccination of infants.

Smith SG, Zelmer A, Blitz R, Fletcher HA, Dockrell HM.

Vaccine. 2016 Oct 17;34(44):5298-5305. doi: 10.1016/j.vaccine.2016.09.002. Epub 2016 Sep 9.

21.

Sleeping Beauty and the Story of the Bacille Calmette-Guérin Vaccine.

Fletcher HA.

MBio. 2016 Aug 30;7(4). pii: e01370-16. doi: 10.1128/mBio.01370-16.

22.

In vitro mycobacterial growth inhibition assays: A tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy.

Tanner R, O'Shea MK, Fletcher HA, McShane H.

Vaccine. 2016 Sep 7;34(39):4656-4665. doi: 10.1016/j.vaccine.2016.07.058. Epub 2016 Aug 12. Review.

23.

Systematic tracking of altered haematopoiesis during sporozoite-mediated malaria development reveals multiple response points.

Vainieri ML, Blagborough AM, MacLean AL, Haltalli ML, Ruivo N, Fletcher HA, Stumpf MP, Sinden RE, Celso CL.

Open Biol. 2016 Jun;6(6). pii: 160038. doi: 10.1098/rsob.160038.

24.

Human biomarkers: can they help us to develop a new tuberculosis vaccine?

Fletcher HA, Dockrell HM.

Future Microbiol. 2016 Jun;11:781-7. doi: 10.2217/fmb.16.15. Epub 2016 May 20. Review.

25.

Human newborn bacille Calmette-Guérin vaccination and risk of tuberculosis disease: a case-control study.

Fletcher HA, Filali-Mouhim A, Nemes E, Hawkridge A, Keyser A, Njikan S, Hatherill M, Scriba TJ, Abel B, Kagina BM, Veldsman A, Agudelo NM, Kaplan G, Hussey GD, Sekaly RP, Hanekom WA; BCG study team.

BMC Med. 2016 May 16;14:76. doi: 10.1186/s12916-016-0617-3.

26.

Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants.

Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M, Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E, Darboe F, Penn-Nicholson A, Nemes E, Hatherill M, Hussey G, Mahomed H, Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H.

Nat Commun. 2016 May 6;7:11633. doi: 10.1038/ncomms11633. No abstract available.

27.

TB vaccine development and the End TB Strategy: importance and current status.

Fletcher HA, Schrager L.

Trans R Soc Trop Med Hyg. 2016 Apr;110(4):212-8. doi: 10.1093/trstmh/trw016. Review.

28.

T-cell activation is an immune correlate of risk in BCG vaccinated infants.

Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M, Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E, Darboe F, Penn-Nicholson A, Nemes E, Hatherill M, Hussey G, Mahomed H, Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H.

Nat Commun. 2016 Apr 12;7:11290. doi: 10.1038/ncomms11290. Erratum in: Nat Commun. 2016 May 06;7:11633.

29.

Association of Human Antibodies to Arabinomannan With Enhanced Mycobacterial Opsonophagocytosis and Intracellular Growth Reduction.

Chen T, Blanc C, Eder AZ, Prados-Rosales R, Souza AC, Kim RS, Glatman-Freedman A, Joe M, Bai Y, Lowary TL, Tanner R, Brennan MJ, Fletcher HA, McShane H, Casadevall A, Achkar JM.

J Infect Dis. 2016 Jul 15;214(2):300-10. doi: 10.1093/infdis/jiw141. Epub 2016 Apr 7.

30.

World TB Day 2016: an interview with leading experts in tuberculosis research.

Phillips PP, Fletcher HA, Abubakar I, Lipman MC, McHugh TD.

BMC Med. 2016 Mar 23;14:55. doi: 10.1186/s12916-016-0591-9.

31.

Distinct Transcriptional and Anti-Mycobacterial Profiles of Peripheral Blood Monocytes Dependent on the Ratio of Monocytes: Lymphocytes.

Naranbhai V, Fletcher HA, Tanner R, O'Shea MK, McShane H, Fairfax BP, Knight JC, Hill AV.

EBioMedicine. 2015 Nov;2(11):1619-26.

32.

T-Cell Responses Are Associated with Survival in Acute Melioidosis Patients.

Jenjaroen K, Chumseng S, Sumonwiriya M, Ariyaprasert P, Chantratita N, Sunyakumthorn P, Hongsuwan M, Wuthiekanun V, Fletcher HA, Teparrukkul P, Limmathurotsakul D, Day NP, Dunachie SJ.

PLoS Negl Trop Dis. 2015 Oct 23;9(10):e0004152. doi: 10.1371/journal.pntd.0004152. eCollection 2015 Oct.

33.

Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.

Schito M, Migliori GB, Fletcher HA, McNerney R, Centis R, D'Ambrosio L, Bates M, Kibiki G, Kapata N, Corrah T, Bomanji J, Vilaplana C, Johnson D, Mwaba P, Maeurer M, Zumla A.

Clin Infect Dis. 2015 Oct 15;61Suppl 3:S102-18. doi: 10.1093/cid/civ609.

34.

Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines.

Smith SG, Smits K, Joosten SA, van Meijgaarden KE, Satti I, Fletcher HA, Caccamo N, Dieli F, Mascart F, McShane H, Dockrell HM, Ottenhoff TH; TBVI TB Biomarker Working Group.

PLoS One. 2015 Sep 14;10(9):e0138042. doi: 10.1371/journal.pone.0138042. eCollection 2015.

35.

Profiling the host response to malaria vaccination and malaria challenge.

Dunachie S, Hill AV, Fletcher HA.

Vaccine. 2015 Sep 29;33(40):5316-20. doi: 10.1016/j.vaccine.2015.07.107. Epub 2015 Aug 6. Review.

36.

Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model.

Dunachie S, Berthoud T, Hill AV, Fletcher HA.

Vaccine. 2015 Sep 29;33(40):5321-31. doi: 10.1016/j.vaccine.2015.07.087. Epub 2015 Aug 7.

37.

Profiling the host immune response to tuberculosis vaccines.

Fletcher HA.

Vaccine. 2015 Sep 29;33(40):5313-5. doi: 10.1016/j.vaccine.2015.07.090. Epub 2015 Aug 2.

PMID:
26241949
38.

Big Data in Vaccinology: Introduction and section summaries.

Kaufmann SH, Fletcher HA, Guzmán CA, Ottenhoff TH.

Vaccine. 2015 Sep 29;33(40):5237-40. doi: 10.1016/j.vaccine.2015.04.078. Epub 2015 May 2. No abstract available.

PMID:
25939278
39.

Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A.

Tanner R, Kakalacheva K, Miller E, Pathan AA, Chalk R, Sander CR, Scriba T, Tameris M, Hawkridge T, Mahomed H, Hussey G, Hanekom W, Checkley A, McShane H, Fletcher HA.

BMC Infect Dis. 2014 Dec 3;14:660. doi: 10.1186/s12879-014-0660-7.

40.

Gene expression and cytokine profile correlate with mycobacterial growth in a human BCG challenge model.

Matsumiya M, Satti I, Chomka A, Harris SA, Stockdale L, Meyer J, Fletcher HA, McShane H.

J Infect Dis. 2015 May 1;211(9):1499-509. doi: 10.1093/infdis/jiu615. Epub 2014 Nov 7. Erratum in: J Infect Dis. 2016 Oct 1;214(7):1127.

41.

TRANSVAC workshop on standardisation and harmonisation of analytical platforms for HIV, TB and malaria vaccines: 'how can big data help?'.

Dutruel C, Thole J, Geels M, Mollenkopf HJ, Ottenhoff T, Guzman CA, Fletcher HA, Leroy O, Kaufmann SH.

Vaccine. 2014 Jul 31;32(35):4365-8. doi: 10.1016/j.vaccine.2014.06.014. Epub 2014 Jun 17.

42.

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response.

Matsumiya M, Harris SA, Satti I, Stockdale L, Tanner R, O'Shea MK, Tameris M, Mahomed H, Hatherill M, Scriba TJ, Hanekom WA, McShane H, Fletcher HA.

BMC Infect Dis. 2014 Jun 9;14:314. doi: 10.1186/1471-2334-14-314.

43.

Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A.

Harris SA, Satti I, Matsumiya M, Stockdale L, Chomka A, Tanner R, O'Shea MK, Manjaly Thomas ZR, Tameris M, Mahomed H, Scriba TJ, Hanekom WA, Fletcher HA, McShane H.

Clin Vaccine Immunol. 2014 Jul;21(7):1005-11. doi: 10.1128/CVI.00128-14. Epub 2014 May 14.

44.

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination.

Harris SA, Meyer J, Satti I, Marsay L, Poulton ID, Tanner R, Minassian AM, Fletcher HA, McShane H.

J Infect Dis. 2014 Apr 15;209(8):1259-68. doi: 10.1093/infdis/jit647. Epub 2013 Nov 23.

45.

Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice.

Griffiths KL, Stylianou E, Poyntz HC, Betts GJ, Fletcher HA, McShane H.

PLoS One. 2013 Oct 23;8(10):e78312. doi: 10.1371/journal.pone.0078312. eCollection 2013.

46.

A helicopter perspective on TB biomarkers: pathway and process based analysis of gene expression data provides new insight into TB pathogenesis.

Joosten SA, Fletcher HA, Ottenhoff TH.

PLoS One. 2013 Sep 16;8(9):e73230. doi: 10.1371/journal.pone.0073230. eCollection 2013.

47.

Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG.

Fletcher HA, Tanner R, Wallis RS, Meyer J, Manjaly ZR, Harris S, Satti I, Silver RF, Hoft D, Kampmann B, Walker KB, Dockrell HM, Fruth U, Barker L, Brennan MJ, McShane H.

Clin Vaccine Immunol. 2013 Nov;20(11):1683-9. doi: 10.1128/CVI.00427-13. Epub 2013 Aug 28.

48.

Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data.

Warimwe GM, Fletcher HA, Olotu A, Agnandji ST, Hill AV, Marsh K, Bejon P.

BMC Med. 2013 Aug 21;11:184. doi: 10.1186/1741-7015-11-184.

49.

The ratio of monocytes to lymphocytes in peripheral blood correlates with increased susceptibility to clinical malaria in Kenyan children.

Warimwe GM, Murungi LM, Kamuyu G, Nyangweso GM, Wambua J, Naranbhai V, Fletcher HA, Hill AV, Bejon P, Osier FH, Marsh K.

PLoS One. 2013;8(2):e57320. doi: 10.1371/journal.pone.0057320. Epub 2013 Feb 20.

50.

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.

Meyer J, Harris SA, Satti I, Poulton ID, Poyntz HC, Tanner R, Rowland R, Griffiths KL, Fletcher HA, McShane H.

Vaccine. 2013 Feb 4;31(7):1026-33. doi: 10.1016/j.vaccine.2012.12.042. Epub 2012 Dec 21.

Supplemental Content

Loading ...
Support Center